NASDAQ:ACER
Delisted
Acer Therapeutics Inc. Stock News
$0.660
+0 (+0%)
At Close: Feb 16, 2024
Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Genetic Metabolic Dieticians International Conference
12:30pm, Friday, 06'th May 2022 GlobeNewswire Inc.
NEWTON, Mass. and GENEVA, May 06, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER) (“Acer”) and its collaboration partner, Relief Therapeutics Holding SA (SIX: RLF, OTCQB: RLFTF, R
Acer Therapeutics to Participate in H.C. Wainwright Global Investment Conference
08:30am, Thursday, 05'th May 2022
NEWTON, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious r
Acer Therapeutics Enrolls First Patient in its Phase 2a Clinical Trial of ACER-801 for Treatment of Moderate to Severe Vasomotor Symptoms Associated with Menopause
12:30pm, Wednesday, 30'th Mar 2022 GlobeNewswire Inc.
Results anticipated in H2 2022 Results anticipated in H2 2022
Acer Therapeutics nabs $48.5M in convertible note and secured loan financing facilities
11:30am, Monday, 07'th Mar 2022 Seeking Alpha
Acer Therapeutics (ACER) entered into convertible note and loan financing facilities for up to $48.5M with affiliates of Marathon Asset Management and SWK.With Marathon, it has $6M…
Acer Therapeutics Secures up to $48.5 Million in Convertible Note and Secured Loan Financing Facilities
11:15am, Monday, 07'th Mar 2022 GlobeNewswire Inc.
NEWTON, Mass., March 07, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serio
Acer Therapeutics GAAP EPS of -$0.31 misses by $0.30, revenue of $0.36M misses by $2.97M
10:26pm, Wednesday, 02'nd Mar 2022 Seeking Alpha
Acer Therapeutics press release (ACER): Q4 GAAP EPS of -$0.31 misses by $0.30.Revenue of $0.36M misses by $2.97M.Ended Q4 2021 with $12.7 million in cash and cash equivalents
Acer Therapeutics Reports Q4 and Full Year 2021 Financial Results and Provides Corporate Update
10:18pm, Wednesday, 02'nd Mar 2022 GlobeNewswire Inc.
NEWTON, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serio
Acer Therapeutics Reports Q4 and Full Year 2021 Financial Results and Provides Corporate Update
10:18pm, Wednesday, 02'nd Mar 2022 GlobeNewswire
NEWTON, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided an update on the Company’s recent corporate developments.
Is Acer Therapeutics, Inc. (ACER) Outperforming Other Medical Stocks This Year? (Revised)
07:44pm, Tuesday, 08'th Feb 2022 Zacks Investment Research
Here is how Acer Therapeutics, Inc. (ACER) and Aptinyx Inc. (APTX) have performed compared to their sector so far this year.
Is Acer Therapeutics, Inc. (ACER) Outperforming Other Medical Stocks This Year? (Revised)
04:08pm, Tuesday, 08'th Feb 2022
Here is how Acer Therapeutics, Inc. (ACER) and Aptinyx Inc. (APTX) have performed compared to their sector so far this year.
Benzinga's Top Ratings Upgrades, Downgrades For February 2, 2022
03:05pm, Wednesday, 02'nd Feb 2022 Benzinga
Upgrades
Oppenheimer upgraded the previous rating for NovoCure Ltd (NASDAQ:NVCR) from Perform to Outperform. NovoCure earned $0.13 in the third quarter, compared to $0.09 in the year-ago quarter. At
Acer Therapeutics to Participate in 2022 BIO CEO & Investor Conference
01:30pm, Tuesday, 01'st Feb 2022 GlobeNewswire Inc.
NEWTON, Mass., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development, and commercialization of therapies for serio
Acer Therapeutics to Participate in 2022 BIO CEO & Investor Conference
08:30am, Tuesday, 01'st Feb 2022
NEWTON, Mass., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development, and commercialization of therapies for serious
Acer Therapeutics and Relief Therapeutics Announce Presentation of Four ACER-001 Posters at the Upcoming SIMD and GMDI Conferences
01:30pm, Thursday, 27'th Jan 2022 GlobeNewswire Inc.
Data to be presented suggests ACER-001 could represent a potential alternative to sodium and glycerol phenylbutyrate for treatment of UCDs Data to be presented suggests ACER-001 could represent a pote
Is Opexa Therapeutics, Inc. (ACER) Outperforming Other Medical Stocks This Year?
02:40pm, Thursday, 13'th Jan 2022 Zacks Investment Research
Here is how Opexa Therapeutics, Inc. (ACER) and Aptinyx Inc. (APTX) have performed compared to their sector so far this year.
